MARKET BRIEF - Navigating the Evolving Landscape of Rare Cancer Trials November 30, 2021

Rupa Doshi, PhD, and Sameena Sharif, PhD, explore the landscape of rare cancer clinical trials, from key considerations for study design and the value of biomarkers to the importance of the patient perspective and the options for speeding much-needed therapies to market.

MARKET BRIEF - Allergic Rhinitis Immunotherapy: Opportunity Analysis & Forecasts to 2028 March 30, 2020

Rose Joachim, PhD, indicates that while a wide variety of OTC therapies exist for the temporary abatement of AR symptoms, allergen-specific immunotherapy is the only truly disease-modifying therapy available for AR.

MARKET BRIEF - Tumor-Infiltrating Lymphocytes: A New Frontier in Cancer Immunotherapy January 13, 2020

Cheryl L. Barton, PhD, and Bianca Piachaud-Moustakis, PhD, believe the role of TIL therapy as an anticancer therapy in melanoma and possibly other solid tumors holds great promise and could become a viable course of treatment in the future.

MARKET BRIEF - Nothing Degrading About Saving Lives: E3 Ligands Recruiting New Drugs Into the Clinic June 4, 2019

Marianna Tcherpakov, PhD, discusses underexploited strategies, traditional approaches that can be optimized, novel techniques beginning to emerge and pay dividends, and results propelling this field toward better clinical outcomes.

MARKET BRIEF - Alzheimer’s Disease Market Report (2016-2026) October 2, 2018

Akiko Fukui, MSc, indicates that amid several failures, the AD pipeline is large and consists of many novel mechanisms, which makes it an exciting market undergoing rapid changes despite its high risk.

MARKET BRIEF - Preferences for Targeted Therapies & Patient-Centric Approaches Drive Transformations in Oncology Drug Delivery Market May 1, 2017

Frost & Sullivan Analyst Piyush Bansal says although chemotherapy has been successfully used for inhibiting cell growth throughout the past few decades, the side effects of chemotherapy have forced researchers to look for some alternative drugs (and how to effectively deliver them) for all types of cancer.

MARKET BRIEF - Miniaturizing Healthcare - From Microelectronics to Nanobiosensing March 3, 2015

Cecilia Van Cauwenberghe, MS, Technical Insights Senior Research Analyst, Frost & Sullivan, reports that the proliferation of lower cost microfluidics-based genomics tools offering improved capabilities and allowing more access to end-users is expected to drive this technology for pharmaceutical and biomedical research throughout the next 5 years.

MARKET BRIEF - Sequestration Haunts Life Science Research Tool Market Into 2014 July 8, 2014

Christi Bird, Senior Industry Analyst, Frost & Sullivan, believes the bleakest outlook provided for the life sciences industry is one without a clear light at the end of the tunnel, and successful companies will buckle down to determine long-term strategies for beating the lackluster numbers expected from a sustained austerity policy.

MARKET BRIEF - Latin America Next-Generation Biosimilars Market: Opportunities & Future Growth March 4, 2014

Lucila Rocca, Healthcare Industry Analyst, Frost & Sullivan, indicates the Latin American Biosimilars market will grow at a significant rate in the next 5 years, and the importance of establishing rigorous regulation will stimulate this market growth.

MARKET BRIEF - The Market for Type 2 Diabetes Therapeutics - Key Findings From a Recent Analysis of Global Drug Development Efforts November 19, 2013

Debbie Toscano, Senior Industry Analyst, Frost & Sullivan, summarizes key findings of Frost & Sullivan’s recent analysis of the type 2 diabetes therapeutics market, which examines in detail the insulin and non-insulin segments of this market on a global level.

MARKET BRIEF - Financial Performance Benchmarking & Competitive Landscape Assessment of Leading CROs November 18, 2013

Adam M. Dion, MS, summarizes GlobalData’s recent CRO Benchmark Report and believes the dynamics of pharmaceutical outsourcing and location decisions in emerging markets are changing. Cost reduction is being augmented and will gradually be eclipsed by footprint growth as a major factor shaping decisions, and CROs are realizing that the ability to be on the ground closer to their customers is a key building block to establishing sustainable, long-term relationships with clients.

MARKET BRIEF - Controlled Release Technologies: Advancing Toward Targeting Therapeutics June 10, 2013

Frost & Sullivan Analyst Cecilia Van Cauwenberghe, MS, reviews a few recent innovative approaches to controlled release technologies with a focus on some of the therapeutic areas most relevant to the current pharmaceuticals market.

MARKET REPORT - Survey Suggests Global Innovation to Recover Much More Quickly Than Expected in 2023 February 9, 2023

After a brief fall in 2022 to a score of 6.5 – the first decline since its inception in 2018 – the index has surged to a record score of 7.4. This sudden recovery in scores over a little more than 8 months bodes extremely well for device and packaging manufacturers in the year ahead, suggesting a strong global recovery in industry outlook and confidence.

2019 Analytical Testing in Drug Development eBook - Regulations Help Propel Testing Market September 6, 2019

This e-Book showcases the various types of services that leading testing companies offer and how they are helping industry comply with regulations to get their products approved and commercialized.

CELL CULTURE MARKET - 3D Cell Cultures: Next Generation & New Challenges November 19, 2015

Kevin James and Robert G. Hunter of BCC Research say significant growth within the biopharmaceuticals industry is spurring unprecedented innovation in and demand for cell culture products for the purposes of drug discovery and safety testing. While 2D cell cultures have been in laboratory use since the 1950s, the market for 3D cultures has witnessed spectacular growth throughout the past decade.

EXECUTIVE INTERVIEW - Respiratory Drug Development: Lonza Experts Share Trends & Key Takeaways October 1, 2024

Beatriz Fernandes, Principal Scientist for R&D, and Kim Shepard, Director, Technology Head Respiratory Delivery, at Lonza, discuss their presentations at RDD 2024, current trends, and the future of the inhalation space.

DRUG DELIVERY - Viewing Lipid Nanoparticle Delivery Technology Through the Lens of a CRDMO September 5, 2024

Lu Tian, PhD, says the complexity of LNP formulations demands diverse and integrated capabilities for development – incorporating lipids, oligonucleotides, small molecules, and sometimes antibodies or ligands, and thus it requires a cohesive approach.

SILICON-STABILIZED HYBRID LNPS - Next-Generation Delivery of RNA Therapeutics September 5, 2024

Suzanne Saffie-Siebert, PhD, Michael Welsh, PhD, Nissim Torabi-Pour, PhD, and Flavia M. Sutera, PhD, review current shortcomings, as well as some accompanying manufacturing challenges, and will show how they can be addressed by SiSaf’s silicon-stabilized hybrid LNPs.

CLINICAL TRIALS - Faithful Migration: Shifting Patient Reported Outcomes From Paper to Electronic September 5, 2024

Melissa Mooney says by following certain steps to faithful migration, the shift to electronic measures is efficient and reliable, especially as there is an increasing body of evidence showing that when minor changes are made to an original measure, the resulting ePRO is likely to be considered equivalent.

Lonza Completes Expansion of Microbial Manufacturing Facility in Visp (CH) ​  September 5, 2024

TECH BRIEF – Expedite FDA Approvals With Certified Pure Materials